These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 36309376)
1. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. Kitasaki N; Hamai Y; Emi M; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Okada M In Vivo; 2022; 36(6):2852-2860. PubMed ID: 36309376 [TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154 [TBL] [Abstract][Full Text] [Related]
3. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy. Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340 [TBL] [Abstract][Full Text] [Related]
4. Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery. Oguma J; Ishiyama K; Kurita D; Kanematsu K; Fujii Y; Kubo K; Yamamoto S; Honma Y; Kato K; Daiko H Esophagus; 2022 Apr; 19(2):214-223. PubMed ID: 34757482 [TBL] [Abstract][Full Text] [Related]
5. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma. Lu H; Liu JF; Rong Y; Liu XB; Wang Y J Gastrointest Surg; 2024 Jun; 28(6):867-869. PubMed ID: 38570232 [TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for esophageal squamous cell carcinoma without pathological lymph node metastasis after neoadjuvant therapy and surgery. Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Kitasaki N; Okada M World J Surg; 2024 Feb; 48(2):416-426. PubMed ID: 38310312 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of nodal status and lymphovascular invasion in patients undergoing neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Miyata H; Sugimura K; Kanemura T; Takeoka T; Sugase T; Yasui M; Nishimura J; Wada H; Akita H; Yamamoto M; Hara H; Shinno N; Omori T; Yano M Dis Esophagus; 2024 Aug; 37(9):. PubMed ID: 38693752 [TBL] [Abstract][Full Text] [Related]
8. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma. Sugase T; Kanemura T; Takeoka T; Matsuura N; Masuike Y; Shinno N; Hara H; Kitakaze M; Kubo M; Mukai Y; Sueda T; Hasegawa S; Akita H; Nishimura J; Wada H; Yasui M; Omori T; Miyata H Anticancer Res; 2024 Jan; 44(1):185-193. PubMed ID: 38159967 [TBL] [Abstract][Full Text] [Related]
9. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery. Tanishima Y; Takahashi K; Nishikawa K; Ishikawa Y; Yuda M; Tanaka Y; Matsumoto A; Yano F; Eto K Esophagus; 2023 Oct; 20(4):651-659. PubMed ID: 37081314 [TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy. Kurokawa T; Hamai Y; Emi M; Ibuki Y; Yoshikawa T; Ohsawa M; Hirohata R; Okada M Anticancer Res; 2020 Aug; 40(8):4387-4394. PubMed ID: 32727767 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery. Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675 [TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy. Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150 [TBL] [Abstract][Full Text] [Related]
13. Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Ohsawa M; Hirohata R; Kitasaki N; Okada M Anticancer Res; 2022 Dec; 42(12):6037-6045. PubMed ID: 36456150 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy. Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242 [TBL] [Abstract][Full Text] [Related]
15. The area of residual tumor predicts esophageal squamous cell carcinoma prognosis following neoadjuvant chemotherapy. Adachi M; Aoyama N; Kojima M; Sakamoto N; Miyazaki S; Taki T; Watanabe R; Matsuura K; Kotani D; Kojima T; Fujita T; Tabuchi K; Ishii G; Sakashita S J Cancer Res Clin Oncol; 2023 Jul; 149(8):4663-4673. PubMed ID: 36201027 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China. Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382 [TBL] [Abstract][Full Text] [Related]
19. Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma. Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Furukawa T; Kurokawa T; Ohsawa M; Okada M Anticancer Res; 2019 Mar; 39(3):1433-1440. PubMed ID: 30842179 [TBL] [Abstract][Full Text] [Related]
20. Development and Validation Study of the Prognostic Impact of Deep Learning-Determined Myxoid Stroma After Neoadjuvant Chemotherapy in Patients with Esophageal Squamous Cell Carcinoma. Kouzu K; Tsujimoto H; Imamura Y; Kajiwara Y; Nearchou IP; Einama T; Takamatsu M; Haraguchi I; Watanabe T; Horiguchi H; Kishi Y; Tsuda H; Watanabe M; Ueno H Ann Surg Oncol; 2024 Sep; 31(9):6300-6308. PubMed ID: 38914836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]